FDG PET/CT for Rheumatic Diseases (Collagen Diseases)
Published on Jan 1, 2020
· DOI :10.1007/978-981-15-0810-3_6
Advanced imaging techniques may enable early diagnosis and monitoring of therapy in various rheumatic diseases. To prevent irreversible tissue damage, inflammatory rheumatic disease must be diagnosed and treated in preclinical stages, requiring highly sensitive detection techniques. PET provides highly sensitive, quantitative imaging at a molecular level, revealing the important pathophysiological processes underlying inflammation. This section provides an overview of the current utility of FDG-PET/CT in patients with active rheumatic diseases such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), spondyloarthritis (SpA), relapsing polychondritis (RPC), adult-onset Still’s disease (AOSD), large vessel vasculitis (LVV), immunoglobulin G4-related disease (IgG4-RD), polymyositis/dermatomyositis (PM/DM), and Granulomatosis with polyangitis (GPA). We also discuss the role of FDG-PET/CT in the diagnosis and monitoring of these diseases.